180 related articles for article (PubMed ID: 32936615)
21. PEG-modification on the endo-position of an antisense oligonucleotide increases tumor accumulation via the EPR effect.
Hagiwara K; Kurihara K; Honma M; Yamamoto J; Shinohara F
J Biomater Sci Polym Ed; 2018 Mar; 29(4):448-459. PubMed ID: 29318941
[TBL] [Abstract][Full Text] [Related]
22. A Long-Circulating Vector for Aptamers Based upon Polyphosphodiester-Backboned Molecular Brushes.
Wang Y; Wang D; Lin J; Lyu Z; Chen P; Sun T; Xue C; Mojtabavi M; Vedadghavami A; Zhang Z; Wang R; Zhang L; Park C; Heo GS; Liu Y; Dong SS; Zhang K
Angew Chem Int Ed Engl; 2022 Oct; 61(41):e202204576. PubMed ID: 35979844
[TBL] [Abstract][Full Text] [Related]
23. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
[TBL] [Abstract][Full Text] [Related]
24. The disposition (ADME) of antisense oligonucleotides.
Dvorchik BH
Curr Opin Mol Ther; 2000 Jun; 2(3):253-7. PubMed ID: 11249618
[TBL] [Abstract][Full Text] [Related]
25. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
26. Fragment-based solid-phase assembly of oligonucleotide conjugates with peptide and polyethylene glycol ligands.
Dirin M; Urban E; Noe CR; Winkler J
Eur J Med Chem; 2016 Oct; 121():132-142. PubMed ID: 27236069
[TBL] [Abstract][Full Text] [Related]
27. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
[TBL] [Abstract][Full Text] [Related]
28. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
29. Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody.
Meissner JM; Toporkiewicz M; Czogalla A; Matusewicz L; Kuliczkowski K; Sikorski AF
J Control Release; 2015 Dec; 220(Pt A):515-528. PubMed ID: 26585505
[TBL] [Abstract][Full Text] [Related]
30. Polyelectrolyte complex micelles composed of c-raf antisense oligodeoxynucleotide-poly(ethylene glycol) conjugate and poly(ethylenimine): effect of systemic administration on tumor growth.
Jeong JH; Kim SH; Kim SW; Park TG
Bioconjug Chem; 2005; 16(4):1034-7. PubMed ID: 16029047
[TBL] [Abstract][Full Text] [Related]
31. Perspectives in antisense therapeutics.
Agrawal S; Iyer RP
Pharmacol Ther; 1997; 76(1-3):151-60. PubMed ID: 9535177
[TBL] [Abstract][Full Text] [Related]
32. Physiochemical properties of low and high molecular weight poly(ethylene glycol)-grafted poly(ethylene imine) copolymers and their complexes with oligonucleotides.
Glodde M; Sirsi SR; Lutz GJ
Biomacromolecules; 2006 Jan; 7(1):347-56. PubMed ID: 16398535
[TBL] [Abstract][Full Text] [Related]
33. Physicochemical properties and nuclease resistance of antisense-oligodeoxynucleotides entrapped in the core of polyion complex micelles composed of poly(ethylene glycol)-poly(L-lysine) block copolymers.
Harada A; Togawa H; Kataoka K
Eur J Pharm Sci; 2001 Apr; 13(1):35-42. PubMed ID: 11292566
[TBL] [Abstract][Full Text] [Related]
34. PEGylation of poly(ethylene imine) affects stability of complexes with plasmid DNA under in vivo conditions in a dose-dependent manner after intravenous injection into mice.
Merdan T; Kunath K; Petersen H; Bakowsky U; Voigt KH; Kopecek J; Kissel T
Bioconjug Chem; 2005; 16(4):785-92. PubMed ID: 16029019
[TBL] [Abstract][Full Text] [Related]
35. Surface functionalized cationic lipid-DNA complexes for gene delivery: PEGylated lamellar complexes exhibit distinct DNA-DNA interaction regimes.
Martin-Herranz A; Ahmad A; Evans HM; Ewert K; Schulze U; Safinya CR
Biophys J; 2004 Feb; 86(2):1160-8. PubMed ID: 14747350
[TBL] [Abstract][Full Text] [Related]
36. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms.
Clementi C; Miller K; Mero A; Satchi-Fainaro R; Pasut G
Mol Pharm; 2011 Aug; 8(4):1063-72. PubMed ID: 21608527
[TBL] [Abstract][Full Text] [Related]
37. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
Lo YL; Liu Y; Tsai JC
Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
[TBL] [Abstract][Full Text] [Related]
38. Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions.
Shi F; Wasungu L; Nomden A; Stuart MC; Polushkin E; Engberts JB; Hoekstra D
Biochem J; 2002 Aug; 366(Pt 1):333-41. PubMed ID: 12030844
[TBL] [Abstract][Full Text] [Related]
39. Antisense oligonucleotide pharmacokinetics and metabolism.
Geary RS
Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):381-91. PubMed ID: 19379126
[TBL] [Abstract][Full Text] [Related]
40. Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides.
Remaut K; Lucas B; Braeckmans K; Demeester J; De Smedt SC
J Control Release; 2007 Feb; 117(2):256-66. PubMed ID: 17188777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
